Mood disorders in family practice: Beyond unipolarity to bipolarity

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 4, Issue 4, 2002, Pages 142-150

  Sloan Manning, J ^a,b,d   Ahmed, Saeeduddin ^c   McGuire, Hillary C ^c   Hay, Donald P ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b BAPTIST MEMORIAL HOSPITAL   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4944247436     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v04n0405     Document Type: Article

References (77)

1. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262:914-919
2. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 Study. JAMA 1995; 274:1511-1517
3. Hays RD, Wells KB, Sherhourne CD, et al Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995; 52:11-19
4. Simon GE, Katon WJ, VonKorff M, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Ann J Psychiatry 2001; 158:1638-1644
5. Lin EH, VonKorff M, Russo J, et al. Can depression treatment in primary care reduce disability? a stepped care approach. Arch Fam Med 2000; 9: 1052-1058
6. Nierenberg AA. DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001; 62(suppl 16):5-9
7. Akiskal HS, Bourgeois ML, Angst J. et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disoid 2000; 59(suppl 1 ):S5-S30
8. Berman RM, Narasimhan M. Charney DS. Treatment-refractory depression: definitions and characteristics. Depress Anxiety 1997; 5:154-164
9. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 133:373-378
10. Dunner DL. Patrick V, Fieve RR. Rapid cycling manic depressive patients. Compr Psychiatry 1977; 18:561-566
11. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62: 249-255
12. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164:549-550
13. Kraepelin E. Manic-Depressive Illness. Edinburgh. Scotland: ES Livingstone; 1921
14. Dunner DL, Gershon ES. Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11:31-42
15. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol Bull 1987; 23:68-73
16. Angst J. Merikangas K. The depressive spectrum: diagnostic classification and course. J Affect Disord 1997; 45:31-39
17. Goodwin FK, Jamison K. Manie-Depressive Illness. New York, NY; Oxford University Press; 1990
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
19. Cassano GB, Dell'Osso L, Frank E, et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999; 54:319-328
20. Regier DA. Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45:977-986
21. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
22. Levvinsohn PM, Klein DN. Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, cornorbidity, and course. J Am Acad Child Adolesc Psychiatry 1995; 34:454-463
23. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50:143-151
24. Allilaire JE, Hantouche EG, Sechter D, et al. Frequency and clinical aspects of bipolar II disorder in a French multicenter study: EPIDEP. Encephale 2001; 27:149-158
25. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 43:163-166
26. Manning JS. Haykal RF. Connor PD. et al. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997; 38:102-108
27. Manning JS, Zylstra RG, Connor PD. Teaching family physicians about mood disorders: a procedure suite for behavioral medicine. Primary Care Companion J Clin Psychiatry 1999; 1:18-23
28. Regier DA. Narrow WE. Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective I-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94
29. Baldessarini RJ, Tondo L. Hennen J, et al. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord 1999; 1:91-97
30. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47:125-134
31. Bowden CL. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 2001; 52:51-55
32. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31:281-294
33. Spitzer RL. Psychiatric diagnosis: are clinicians still necessary? Compr Psychiatry 1983; 24:399-411
34. Simpson SG, Folstein SE, Meyers DA, et al. Bipolar II: the most common bipolar phenotype? Am J Psychiatry 1993; 150:901-903
35. Dunner DL. Tay LK. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry 1993; 34:303-307
36. Benazzi F. Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci 2001; 251:32-34
37. Wicki W, Angst J. The Zurich Study, X: hypomania in a 28- to 30-year-old cohort. Eur Arch Psychiatry Clin Neurosci 1991; 339-348
38. Akiskal H, Maser D. Zeller PJ, et al. Switching from "unipolar" to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995; 52:114-123
39. Frances AJ, Kahn DA, Carpenter D, et al. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998; 59(suppl 4):73-79
40. Shelton RC, Tollefson CD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134
41. Benazzi F. Prevalence of bipolar II disorder in atypical depression. Eur Arch Psychiatry Clin Neurosci 1999; 249:62-65
42. Kretschmer E. Physique and Character. New York, NY: Macmillan Publishing Co: 1936
43. Akiskal HS. Perugi G, Hantouche EG, et al. The affective temperament scales of Memphis, Pisa, Paris, and San Diego: progress towards a selfrated auto-questionnaire version (TEMP-A), J Affect Disord 2002. In press
44. Akiskal HS. The temperamental borders of affective disorders. Acta Psychiatr Scand Suppl 1994; 379:32-37
45. Lapalme M, Hodgins S, LaRoche C. Children of parents with bipolar disorder: a meta-analysis of risk for mental disorders. Can J Psychiatry 1997; 42:623-631
46. Hirsehfeld RM, Williams JB, Spitzer RL. et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873-1875
47. Peet M. Pratt JP. Lithium: current status in psychiatric disorders. Drugs 1993; 46:7-17
48. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63:508-512
49. Goodwin FK, Jamison KR. Maintenance medical treatment. In: Goodwin FK. Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:665-724
50. De Leon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry 2001; 9:209-222
51. Bowden CL. Calabrese JR. McElroy SL, et al, for the Divalproex Maintenance Study Group. A randomised, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57:481-489
52. Baetz M. Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998; 43:73-77
53. Keck PE Jr, Taylor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33:542-546
54. Keck PE Jr. McElroy SL. Tugrul KC, et al. Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 1993; 27:150-153
55. Sonne SC. Brady KT. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am 1999; 22:609-627
56. Young LT, Robb JC, Hasey CM, et al. Gabapentin as an adjunetive treatment in bipolar disorder. J Affect Disord 1999; 55:73-77
57. Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999; 60:245-248
58. Pande AC, Crockatt JG, Janney CA, et al, tor the Gabapentin Bipolar Disorder Study Group. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Diaord 2000; 2:249-255
59. Calabrese JR. Bowden CL, Sachs GS. et al, for the Lamictal 602 Study Group. A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
60. Calabrese JR, Suppes T, Bowden CL, et al. for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61:841-850
61. Manning JS, Haykal RF, Connor PD, et al. Depressed women with cyclothymic temperament: sustained remission with lamotrigine. J Affect Disord 2002. In press
62. Tohen M. Sanger TM, McElroy SL. et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702-709
63. Tohen M. Jacobs TG, Grundy SL, et al, for the Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841-849
64. Tohen M, Baker RW, Altshuler L, et al. Olanzapine versus divalproex for the treatment of acute mania. Presented at the 14th annual congress of the European College of Neuropsychopharmacology; Sept 9, 2001; Munich, Germany
65. Zajecka JM. Weisler R, Swann AC. et al. Divalproex sodium vs olanzapine for the treatment of mania in bipolar disorder. Presented at the 39th annual meeting of the American College of Neuropsycbopbarmacology: Dec 10, 2000; San Juan, Puerto Rico
66. Kinon BJ, Basson BR, Gilmore JA. et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100
67. Basson B, Kinon BJ, Taylor C. et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001; 62:231-238
68. Tohen M. Risser R. Baker RW, et al. Olanzapine in the treatment of bipolar depression, in: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 22, 2002; Philadelphia. Pa. Abstract NR489:132
69. Tohen M, Vieta E. Ketter T. et al. Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression. Presented at the 155th annual meeting of the American Psychiatric Association; May 18, 2002; Philadelphia, Pa
70. Tohen M, Chengappa KNR. Suppes T, et al. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18month study. Presented at the 23rd annual meeting of the Congress of the Collegium Internationale Neuro-Psychopharmacologicurn: June 25, 2002; Montreal, Canada
71. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002: 159(suppl4):1-50
72. Tohen M. Chengappa KN. Suppes T. et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59:62-69
73. Bunney WE Jr, Goodwin FK, Murphy DL, et al. The "switch process" in manic-depressive illness, 2: relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry 1972; 27:304-309
74. Menchon JM, Gasto C, Vallejo J, et al. Rate and significance of hypomanic switches in unipolar melancholic depression. Eur Psychiatry 1993; 8: 125-129
75. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-1138
76. Post RM. Denicoff KD, Leverich GS, et al. Drug-induced switching in bipolar disorder. CNS Drugs 1997; 8:352-365
77. Benazzi F. Antidepressant-assodated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 46:73-77